维持性血液透析合并高尿酸血症患者的临床治疗研究进展

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract]Renal insufficiency is a risk factor for hyperuricemia,and studies have shown that hyperuricemia is prone to endothelial dysfunction.For patients with maintenance hemodialysis with hyperuricemia,because of the side effects of drugs and the inaccurate treatment effect,there is no standardized clinical treatment standard,which leads to different clinical treatment options.This study reviewed the clinical treatment of patients with maintenance hemodialysis combined with hyperuricemia,and provided recommendations for further guidance on related treatments.

Key words： Hemodialysis Hyperuricemia Endothelial dysfunction Treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I7/24

[1]	Tsai CW，Chiu HT，Huang HC，et al.Uric acid predicts adverse outcomes in chronic kidney disease：a novel insight from trajectory analyse[J].Nephrol Dial Transplant，2018，33（2）：231-241.
[2]	Alshahawey M，Shahin SM，Elsaid TW，et al.Effect of Febuxostat on the endothelial dysfunction in hemodialysis patients：a randomized，placebo-controlled，double-blinded study[J].Am J Nephrol，2017，45（5）：452-459.
[3]	Yuki T，Kan K，Yukio T，et al.Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia：a randomized controlled study[J].Hemodialysis Int，2015，19（4）：514-520.
[4]	Alem MM.Allopurinol and Endothelial function：a systematic review with Meta-analysis of randomized controlled trials[J].Cardiovasc Ther，2018，36（4）：e12432.
[5]	Keenan T，Zhao W，Rasheed A，et al.Causal assessment of serum uratelevels in cardiometabolic diseases through a mendelian randomization study[J].J Am Coll Cardiol，2016，67（4）：407-416.
[6]	Kttgen A，Albrecht E，Teumer A，et al.Genome-wide association analyses identify 18 new loci associated with serum urate concentrations[J].Nat Genet，2013，45（2）：145-154.
[7]	Matsuo H，Nakayama A，Sakiyama M，et al.ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcre-tion and renal urate overload[J].Sci Rep，2014，4（1）：3755.
[9]	Okafor ON，Farrington K，Gorog DA.Allopurinol as a therapeutic option in cardiovascular disease[J].Pharmacol Ther，2017，172：139-150.
[10]	Feig DI，Kang DH，Johnson RJ，et al.Uric acid and cardiovascular risk[J].N Engl J Med，2008，359（17）：1811-1821.
[14]	Vargas-Santos AB，Neogi T.Management of gout and hyperuricemia in CKD[J].Am J Kidney Dis，2017，70（3）：422-439.
[22]	刘丽秋，赵震霄，赵秀珍.氯沙坦治疗尿毒症血液透析病人高血压的临床研究[J].青岛大学医学院学报，2001，37（4）：20.
[8]	Richette P，Perez-Ruiz F，Doherty M，et al.Improving cardiovascular and renal outcomes in gout：what should we target?[J].Nat Rev Rheumatol，2014，10（11）：654-661.
[11]	Perez-Ruiz F，Martinez-Indart L，Carmona L，et al.Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout[J].Ann Rheum Dis，2014，73（1）：177-182.
[12]	George J，Carr E，Davies J，et al.Highdose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid[J].Circulation，2006，114（23）：2508-2516.
[13]	Tsuruta Y，Nitta K，Akizawa T，et al.Association between allopurinol and mortality among Japanese hemodialysis patients：Results from the DOPPS[J].Int Urol Nephrol，2014，46（9）：1833-1841.
[15]	Keenan RT，O′Brien WR，Lee KH，et al.Prevalence of contraindications and prescription of pharmacologic therapies for gout[J].Am J Med，2011，124（2）：155-163.
[16]	Hira D，Chisaki Y，Noda S，et al.Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment[J].Pharmacology，2015，96（1-2）：90-98.
[17]	Mukoyoshi M，Nishimura S，Hoshide S，et al.In vitro drugdrug interaction studies with febuxostat，a novel non-purine selective inhibitor of xanthine oxidase：plasma protein binding，identification of metabolic enzymes and cytochrome P450 inhibition[J].Xenobiotica，2008，38（5）：496-510.
[18]	Tsuruta Y，Kikuchi K，Tsuruta Y，et al.Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia：a randomized controlled study[J].Hemodial Int，2015，19（4）：514-520.
[19]	Yilmaz MI，Saglam M，Caglar K，et al.The determinants of endothelial dysfunction in CKD：oxidative stress and asymmetric dimethylarginine[J].Am J Kidney Dis，2006，47（1）：42-50.
[20]	Mitsuboshi S，Yamada H，Nagai K，et al.Comparison of clinical advantage between Topiroxostat and Febuxostat in hemodialysis patients[J].Biol Pharm Bull，2017，40（9）：1463-1467.
[21]	Wu XW，Lee CC，Muzny DM，et al.Urate oxidase：primary structure and evolutionary implications[J].Proc Natl Acad Sci USA，1989，86（23）：9412-9416.
[23]	Zinman B，Wanner C，Lachin JM，et al.Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J].N Engl J Med，2015，373（22）：2117-2128.
[24]	Neal B，Perkovic V，Mahaffey KW，et al.Canagliflozin and cardiovascular and renal events in type 2diabetes[J].N Engl J Med，2017，377（7）：644-657.
[25]	Mahaffey KW，Neal B，Perkovic V，et al.Canagliflozin for primary and secondary prevention of cardiovascular events：Results from the CANVAS program（Canagliflozin cardiovascular assessment study）[J].Circulation，2018，137（4）：323-334.